


## PHARMACEUTICAL 2019



## Amneal Pharmaceuticals Inc. Rank 84 of 371





## PHARMACEUTICAL 2019



## Amneal Pharmaceuticals Inc. Rank 84 of 371



The relative strengths and weaknesses of Amneal Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amneal Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 216% points. The greatest weakness of Amneal Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 345% points above the market average of -331%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 1,286,644         |
| Cost of Goods Sold                          | 946,588           |
| Intangible Assets                           | 2,081,195         |
| Liabilities, Current                        | 553,850           |
| Liabilities, Non-Current                    | 2,902,523         |
| Other Assets                                | 440,751           |
| Other Compr. Net Income                     | 177,966           |
| Other Expenses                              | 332,332           |
| Other Liabilities                           | 0                 |
| Other Net Income                            | -160,749          |
| Property and Equipment                      | 544,146           |
| Research and Development                    | 194,190           |
| Revenues                                    | 1,662,991         |
| Selling, General and Administrative Expense | 230,435           |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 4,352,736         |
| Liabilities              | 3,456,373         |
| Expenses                 | 1,703,545         |
| Stockholders Equity      | 896,363           |
| Net Income               | -201,303          |
| Comprehensive Net Income | -112,320          |
| Economic Capital Ratio   | 14%               |